2024-10-24 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

**Company Overview:** Eli Lilly and Co. is a leading pharmaceutical company that develops and manufactures a wide range of pharmaceutical products.

**Performance Analysis:**

**1. Relative Performance:**

* **Cumulative Return:** LLY: 871.93%, VOO (S&P 500): 136.39%.
* **Outperformance:** LLY has significantly outperformed the S&P 500, with a cumulative return difference of 735.54%. This represents a relative outperformance position of 91.31% based on historical data. 

**2. Recent Price Movements:**

* **Closing Price:** $906.0
* **5-Day Moving Average:** $912.73
* **20-Day Moving Average:** $906.36
* **60-Day Moving Average:** $903.5

The stock is currently trading slightly below its 5-day moving average, indicating potential short-term downward pressure. However, it is above both the 20-day and 60-day moving averages, suggesting a generally bullish trend.

**3. Technical Indicators:**

* **RSI:** 56.8 - The RSI indicates that the stock is slightly overbought, but not in a dangerously overbought territory.
* **PPO:** 0.02 - The PPO is a momentum indicator that suggests a positive trend, but at a relatively low level.
* **Delta_Previous_Relative_Divergence:** -2.91 - This suggests that the stock's relative outperformance against the market has weakened in the past 20 days.
* **Expected Return:** 48.08% - This indicates that the stock is expected to generate a significant long-term (2+ years) outperformance compared to the S&P 500. 

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | $11.30 B |
| 2024-04-30 | 2.49 | $8.77 B |
| 2023-11-02 | -0.06 | $9.50 B |
| 2023-08-08 | 1.96 | $8.31 B |
| 2024-08-08 | 1.96 | $8.31 B |

* **Latest Earnings:** The company reported EPS of $3.29 and revenue of $11.30 billion for the quarter ending 2024-08-08. This exceeded analysts' expectations, signaling positive growth momentum.

**5. News and Recent Developments:**

* **Recent Market Outlook:** Based on FINBOLD data, the market outlook for LLY is positive, with analysts highlighting the company's strong pipeline, growing market share in key therapeutic areas, and potential for future growth.
* **Analyst Opinions:** The majority of analysts have a "Buy" or "Strong Buy" rating on LLY, with a median price target of $105.00.
* **Performance Highlights:** LLY has recently received recognition for its innovative drug development, successful launches, and strong financial performance. 

**Overall Analysis:**

LLY is a strong performer with a solid track record of outperformance compared to the broader market. The company exhibits positive financial performance, a strong pipeline, and favorable analyst sentiment. While recent technical indicators suggest short-term consolidation, the long-term outlook for LLY remains positive, making it a potentially attractive investment for investors seeking growth and long-term value. 
